Aleksandar Sič: The Endothelium and Cardiovascular Toxicity in Blood Cancers
Aleksandar Sič, Review Editor at Frontiers, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Diseases, adding:
“I have just published another interesting paper with the team from North Central Bronx Hospital and colleagues from Serbia and Bosnia and Herzegovina.
Cardiovascular toxicity in patients with blood cancers is often explained mainly through damage to the heart muscle.
We focused instead on the endothelium and its possible role in connecting several complications that are usually discussed separately.
The paper also explains how the malignancy itself, anticancer treatment, immune activation and stem cell transplantation can damage blood vessels and contribute to hypertension, thrombosis, coronary microvascular dysfunction and myocardial dysfunction.
We also discuss whether blood markers of endothelial injury could help identify patients at risk earlier.
By all means interesting for reading.
‘Endothelial Injury as a Potential Contributor to Cardiovascular Toxicity in Hematologic Malignancies’ is now available in Diseases.”
Title: Endothelial Injury as a Potential Contributor to Cardiovascular Toxicity in Hematologic Malignancies
Authors: Aladin Altić, Nikola Jovanovic, Dario Vucic, Nikolaos Katsivelos, Lydia Giannakou, Jongyeob Kim, Ali Maaz, Una Tonkovic, Aleksandar Sič, Marko Baralic
Stay updated with Hemostasis Today.
-
Sep 16, 2026, 15:45Matthew Hazell: A Brilliant Explanation of Phenotype vs Genotype Using a LEGO House
-
Sep 16, 2026, 15:23Ahmad Al-Ramahi: Presenting the Military Pharmacists Blood Training Course at the FIP World Congress
-
Sep 16, 2026, 15:21HIT Reimagined: Can 12-Lipoxygenase Inhibition Stop Immune Thrombosis?
-
Sep 16, 2026, 14:42Ruchi Punamia: Beyond the Blood Bank and The Clinical Impact of Apheresis
-
Sep 16, 2026, 14:06Kalyan Roy: Celebrating Apheresis, Advancing Care, Saving Lives
-
Sep 16, 2026, 13:38Andrew Zapfel: Advancing Sickle Cell Disease Care and Research
-
Sep 16, 2026, 13:30Thirunavukkarasu Angappan: Why Plasma-Derived Factor VIII Still Matters for Inhibitor Patients
-
Sep 16, 2026, 13:22Matthew Hazell: New BSH Guidance for Fetal, Neonatal and Paediatric Transfusion
-
Sep 16, 2026, 13:21Sophia Delicou: Mediterranean Network for Haemoglobinopathies and Regional Collaboration